Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Extensive DCIS and microcalcifications in patients with breast cancer reaching pCR after NAC

Tanja Gagliardi, MD; Ashutosh Nerurka, MD; Marios Tasoulis MD, PhD, FEBS, FRCS; and Nicolò Battisti, MD; members of the clinical radiology, pathology, medical oncology and breast surgery teams at The Royal Marsden NHS Foundation Trust, London, UK, discuss the findings of a study assessing the impact of microcalcifications in patients with breast cancer achieving a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). 26 patients with an extensive in situ component and microcalcifications who achieved a pCR of their invasive disease following NAC were retrospectively reviewed. Three patients had loco-regional recurrence, all of whom had persistent DCIS and microcalcifications. Analyses showed that microcalcifications post-NAC were not associated with tumor characteristics, did not reflect treatment responses, and were not a marker for persistent ductal carcinoma in situ. The study raises questions regarding the impact of DCIS on disease recurrence and loco-regional management of these patients. Larger studies are needed to further understand these trends. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

Disclosures

N. Battisti reports travel grants: Pfizer, Lilly, Genomic Health; speaker fees: Pfizer, AbbVie